BLUE - Stock Analysis & Overview

About bluebird bio, Inc.

Biotechnology

Healthcare

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia...

bluebird bio, Inc. Key Metrics

Market Cap: $96M
52 Weeks Low: $0.48
52 Weeks High: $5.53
P/B: 0.73x
P/E: -0.32x
P/S: 2.10x

Upcoming Events

BLUE Analyst Forecasts

‌

BLUE Financials

BLUE Income Statement Key Metrics

Revenue(TTM)45.69 M
Gross Profit(TTM)-10.33 M
EBITDA(TTM)-227.23 M
Net Income(TTM)-302.96 M
EPS Diluted(TTM)-1.69

Decode BLUE's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

BLUE earnings and revenue history

BLUE Return on Equity

See how efficiently BLUE generates profit for it's shareholders.

100

Poor

Average

Strong

Return on Equity Growth

BLUE's Return on Equity has grown significantly over the past 10 years, increasing by over 27.08%.

BLUE Revenue Growth

See how BLUE has grown it's revenue over the past 10 years.

‌

Revenue Growth

BLUE's revenue has shown poor growth over the past 10 years, increasing by only 1.50%.

bluebird bio, Inc.

Page title

Section title